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Abstract The objective of this study is to examine the
efficacy of gabapentin for the treatment of hemicrania
continua (HC) in cases where patients had difficulty tol-
erating indomethacin due to adverse effects. A retrospec-
tive chart review of nine patients with HC between October
2006 and February 2008. Inclusion criteria included men
and women age 18 or above presenting to the headache
center with a headache that meets International Headache
Society criteria for HC including a response to indometh-
acin, but were not able to continue on indomethacin sec-
ondary to adverse effects. Four patients report being pain
free, three patients report a 50–80% reduction of pain, one
patient reports a 10% reduction of pain, and one patient
reports no change in pain. Seven out of nine patients
demonstrated at least a 50% reduction of pain on gaba-
pentin, four patients becoming completely pain free.
Keywords Hemicrania continua  Gabapentin 
Efficacy  Pain free
Introduction
Hemicrania continua (HC) is an uncommon primary head-
ache disorder characterized by a continuous, mild to mod-
erate intensity, unilateral headache [1–4]. Most patients will
experience superimposed exacerbations of more severe pain,
often associated with ipsilateral autonomic symptoms.
Diagnostic criteria for HC are as follows: [5].
Headache for greater than 3 months fulfilling the fol-
lowing criteria:
All of the following:
Unilateral pain without side shift, daily and continuous,
without pain-free periods, moderate intensity, but with
exacerbations of severe pain.
At least one of the following autonomic features occurs
during exacerbations and ipsilateral to the side of pain:
Conjunctival injection and/or lacrimation, nasal conges-
tion and/or rhinorrhea, ptosis and/or miosis.
A complete response to therapeutic doses of indo-
methacin.
Finally, not attributed to another disorder.
There is a group of patients that meets the above criteria
for HC, but has to discontinue indomethacin secondary to
adverse effects, primarily involving the gastrointestinal
(GI) tract. The side effects can range from gastritis to
severe bleeding, patients may also develop an allergy to
indomethacin, see an elevation of blood pressure, or an
exacerbation of asthma symptoms.
Gabapentin is often used in an off label fashion for the
treatment of neuropathic pain and is well tolerated from a
side effect profile. Marinano da Silva, Alcantara, Bordini,
and Speciali reported a case of a unilateral headache sim-
ilar to HC that was responsive to gabapentin [6].
Methods
Institutional Review Board approval was obtained for the
study. A retrospective chart review of nine patients with
HC between October 2006 and February 1, 2008. Inclu-
sion criteria included men and women age 18 or above
presenting to the headache center with a headache that
meets IHS criteria for HC, including a response to indo-
methacin, but were unable to continue on indomethacin
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secondary to adverse side effects. Exclusion criteria
included anyone under the age of 18 and anyone not
meeting IHS criteria for HC including an adequate trial at
therapeutic doses of indomethacin and response to indo-
methacin. Patients with concomitant disease, specifically
involving pain were not excluded, although every effort
was made to enroll patients where HC was their primary
complaint. The primary end point was at least a 50%
reduction of pain. This was decided since the purpose of
this study was to examine gabapentin as an alternative
therapy, indomethacin remains the gold standard. The
secondary end point was becoming pain-free. Points of
measurement included the duration of disease which is
considered to be from onset to completion of the study,
temporal profile, duration of therapy, range of dose, and
concurrent use of other medications for pain, concomitant
disease, especially related to pain, reduction of pain, and
the side effects of gabapentin. Onset of relief on gaba-
pentin was not measured.
Results
This study included eight women and one man (see
Table 1). The age ranged from 36 to 74 years. The duration
of therapy on gabapentin ranged from 3 months to
13 months with eight out of nine patients remaining on
gabapentin at the end of the study. One patient discontin-
ued after reaching 3,600 mg a day due to lack of efficacy.
The other doses ranged from 600 mg to 3,600 mg per day
of gabapentin. Two patients reported concurrent use of
other medications for pain control. One patient also on
fentanyl patch 50 mcg every 72 h reported an 80%
reduction in pain after reaching 2,400 mg of gabapentin.
The second patient was taking topiramate and became pain
free upon reaching 600 mg of gabapentin.
The seven patients that achieved the primary end point
and reported a 50–80% reduction of pain had doses ranging
from 900 to 3,600 mg per day. The one man reported a
50% reduction of pain and reached the maximum dose of
3,600 mg of gabapentin per day.
Four patients achieved the secondary end point and
reported being completely pain free on gabapentin. The
dose ranges for these patients were, 600 mg, 900 mg,
1,500 mg, and 1,800 mg/day respectively. It should be
noted that one of the four patients was also taking topira-
mate, which has been reported to be efficacious for HC [7,
8].
Two patients failed to achieve either the primary or
secondary end points. The patient, who reported no benefit,
responded to indomethacin on two separate occasions but
developed GI bleeding as a result of indomethacin. The
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The major side effects reported on gabapentin include
sedation, cognitive impairment, depression, and weight
gain. None of the patients chose to discontinue gabapentin
as a result of the above side effects.
Discussion
HC was first described in 1981 and officially named by
Sjaastad and Spierings in 1984 [9, 10]. There are now more
than 100 reports of HC in the literature. HC was originally
believed to be a rare primary headache disorder but more
recent evidence suggests that HC is not rare, just under
recognized [2]. In the clinical setting, HC is characterized
by a unilateral headache that is continuous and of mild to
moderate severity. The pain is usually reported as dull,
aching, or pressure-like pain without associated symptoms.
Exacerbations or more severe pain, lasting anywhere from
20 min to several days, are experienced in the majority of
those with HC, and when present are associated with
one or more autonomic symptoms on the ipsilateral side.
Migrainous features, such as photophobia, phonophobia,
nausea, and vomiting commonly occur during exacerba-
tions of pain. Many patients will experience a sensation of
a foreign body in their eye similar to sand or an eyelash on
the affected side. The pathophysiology of HC is not known,
some scientist believe it is a subtype of migraine, while
others believe it is more closely related to the trigeminal
autonomic cephalalgias (TAC). It was hoped that func-
tional brain imaging would help to clarify our under-
standing of HC, but it revealed that HC is a distinct
headache syndrome, not belonging to the migraine or TAC
group. The scans revealed activation of the contralateral
posterior hypothalamus and ipsilateral dorsal rostral pons,
as well as activation of the ipsilateral ventrolateral mid-
brain, extending over the red nucleus and substania nigra
and the bilateral pontomedullary junction [11]. These areas
have been previously demonstrated to be the sites of acti-
vation in the TACs and migraine, ipsilateral activation
hypothalamic activation in short-lasting unilateral neural-
giform headache attacks with conjunctival injection and
tearing (SUNCT) and cluster; in HC the findings are
reversed. HC was not included in the first edition of the
ICHD-I [12], but is included within the other primary
headaches section of the second edition of the ICHD-II [5].
Hemicrania continua presents as two temporal profiles:
an episodic form with distinct headache phases separated
by periods of pain-free remissions, and a chronic form in
which the headache persists without remission for years
[3]. HC is chronic from onset in 53% of patients; the dis-
order began in the episodic form and evolved into the
chronic form in 35%, and it begins and remains episodic in
12% of patients [2].
Hemicrania continua may be incorrectly diagnosed as
cluster headache. This can occur by focusing exclusively
on the ipsilateral autonomic features that accompany the
painful exacerbations of HC. Similarly, focusing on the
associated photophobia, phonophobia, nausea, and vomit-
ing that may occur during exacerbations of HC may lead to
misdiagnosing HC as migraine. An absolute response to
therapeutic doses of indomethacin helps distinguish HC
from chronic migraine. Autonomic features on the ipsilat-
eral side, which are present during exacerbations of HC,
are at times also present during acute attacks of migraine.
HC is also distinguished from cluster headache and
migraine by the presence of a continuous baseline head-
ache that is usually unilateral and mild to moderate in
severity. The associated features of photophobia, phono-
phobia, nausea, and vomiting, as well as the ipsilateral
autonomic features of cluster are absent with the continu-
ous baseline pain of HC.
Some patients are unable to tolerate indomethacin due
to GI distress, renal disease, or concurrent anticoagulation
therapy, and alternative types of therapy must be con-
sidered. Peres and Silberstein demonstrated in a study
using cyclooxygenase-2 inhibitors (COX-2), efficacy of
celecoxib and rofecoxib, the latter of which has since
been removed from the market. They found 60% of
patients who received celecoxib and 33% who received
rofecoxib experienced a complete response [13]. There is
one case in the literature of a unilateral headache similar
to HC that did not respond to indomethacin, and many
other standard headache agents, but was responsive to
gabapentin at 1,200 mg per day. That patient had com-
plete pain relief after 17 years of continuous headache.
[6]. There have also been two separate reports of mela-
tonin being efficacious for HC, one case reported by
Spears [14], and three cases by Rozen [15]. There have
also been four cases in the literature of patients
responding to topiramate, one by Camarda et al. [16], one
by Matharu et al. [7], and two cases by Brighina et al. [8].
Rozen also reported one case responsive to verapamil
[17].
Gabapentin is an antiepileptic drug that is approved for
use in the adjunctive treatment of partial seizures with and
without secondary generalization in patients over 12 years
of age. Gabapentin is also indicated as adjunctive therapy
in the treatment of partial seizures in pediatric patients age
3–12 years of age. Gabapentin is also indicated for the
management of post herpetic neuralgia in adults. Benefit
has been reported in gabapentin treatment for hypobaric
hypoxia-induced headache, high altitude headache, num-
mular headache, SUNCT syndrome, chronic cluster head-
ache, post-dural puncture headache, and primary
thunderclap headache just to mention headaches disorders
[18–26].
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The mechanism by which gabapentin exerts its analgesic
action is unknown, but in animal models of analgesia,
gabapentin prevents allodynia (pain related behavior in
response to a normally innocuous stimulus) and hyperal-
gesia (exaggerated response to painful stimuli). Gabapentin
also decreases pain related responses after peripheral
inflammation [27].
The mechanism by which gabapentin exerts its anti-
convulsant action is unknown, but in animal test systems
designed to detect anticonvulsant activity, gabapentin
prevents seizures. Gabapentin is structurally related to the
neurotransmitter gamma-aminobutyric acid (GABA) but
does not modify GABA a or GABA b radioligand binding,
it is not converted metabolically into GABA or a GABA
agonist, and it is not an inhibitor of GABA uptake or
degradation. Gabapentin was tested in radioligand binding
assays and did not exhibit affinity for a number of other
common receptor sites including benzodiazepine, gluta-
mate, N-methyl-D-aspartate (NMDA), quisqualate, kainate,
strychnin-insensitive glycine, alpha 1, alpha 2, or beta
adrenergic, adenosine A1 or A2, cholinergic muscarinic or
nicotinic, dopamine D1 or D2, histamine H1, serotonin S1
or S2, opiate mu, delta or kappa, cannabinoid 1, voltage
sensitive calcium channel sites labeled with nitrendipine or
diltiazem, or at voltage sensitive sodium channel sites
labeled with batrachotoxinin A 20 alpha benzoate. Gaba-
pentin also did not alter the cellular uptake of dopamine,
noradrenaline or serotonin.
One patient reported an 80% reduction of pain on
2,400 mg of gabapentin but was also on the fentanyl patch.
There have been reports in the literature of enhancement of
pain control on the combination of opioids and gabapentin
[28, 29]. It should be noted that this patient was taking
opioids for a concomitant condition. This patient met the
primary endpoint, but the concomitant use of an opioid is a
confounding factor.
Conclusions
This study demonstrates that gabapentin is a good choice
for alternative therapy in the treatment of HC. Seven out of
nine patients demonstrated at least a 50% reduction of pain
on gabapentin, four patients becoming completely pain
free. The results of the study are confounded in two
patients that were taking concomitant medications specif-
ically fentanyl patch and topiramate. Another potential
confounding factor is that a proton pump inhibitor was not
initiated when patients had difficulty tolerating indometh-
acin. Clinically it may be prudent to first try initiating
therapy with a proton pump inhibitor while continuing
indomethacin prior to changing to gabapentin. HC is a
particularly difficult headache disorder to treat if the patient
is not able to tolerate indomethacin, therefore alternative
therapies are being sought to provide relief to this patient
population. The results of this study should be validated in
a double-blinded randomized control trial.
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